Low molecular weight dextran of iron: is it safely for treatment of anemia in patients with chronic kidney disease?
Abstract
In this work literature data conserning iron compounds used for intravenous administration in patients with CKD treated by dialysis were summarized. Special attention is paid to low molecular weight dextran of iron (Cosmofer) registered in 2008 and being successfully used during a significant period of time in the United States. It is already registered in 50 countries besides Russia. Analysis of published data allows us make an unambiguous conclusion that Cosmofer provides practically equal safety and efficacy as Venofer - already well-known drug in Russian market. On the other hand, due to some structural features a single-step use of large doses of Cosmofer is possible. This saves time of the personnel and makes therapy cheaper.
About the Authors
V. M. Ermolenko
Кафедра нефрологии и гемодиализа ГОУ ДПО РМАПО Росздрава, г. Москва
Russian Federation
Russian Federation
N. A. Mikhaylova
Кафедра нефрологии и гемодиализа ГОУ ДПО РМАПО Росздрава, г. Москва
Russian Federation
Russian Federation
S. . Baterdene
Кафедра нефрологии и гемодиализа ГОУ ДПО РМАПО Росздрава, г. Москва
Russian Federation
Russian Federation
References
1. Российские Национальные Рекомендации по диагностике и лечению анемии при хронической болезни почек // Анемия. 2006. № 3. С. 3-18.
2. Фесюк А.Ф. Мордик А.И., Борисова Е.В. и др. Применение препарата «венофер» для коррекции дефицита железа у пациентов, находящихся на программном гемодиализе // Тер. архив. 2003. № 8. С. 59-61.
3. Agarwal R., Rizkala A., Kaskas M. et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease // Kidney int. 2007. Vol. 72. P. 638-642.
4. Agarwal R., Vasavada N., Sachs N., Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease // Kidney int. 2004. Vol. 65. P. 2279-2289.
5. Ahsan N. et al. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study // Am J Soc Nephrol. 1998. Vol. 9. P. 664-668.
6. Alfrey A. Toxicity of tubule fluid iron in the nephritic syndrome // Am J Physiol. 1992. Vol. 263. F637-F641.
7. Auerbach M., Ballard H., Trout R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial // J Clin Oncol. 2004. Vol. 22. P. 1301-1307.
8. Auerbach M., Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease // Kidney int. 2008. Vol. 73. P. 528-530.
9. Auerbach M., Winchester J., Wahag A. et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients // Am J Kidney Dis. 1998. Vol. 31. P. 81-86.
10. Auerbach M., Witt D., Toler W. et al. Clinical use of the total dose infusion of iron dextran // J Lab Clin Med. 1988. Vol. 111. P. 566-570.
11. Avasthi R., Aggarval M., Kataria S. Meningismus following intravenous iron dextran // J Ass Physician India. 1991. Vol. 39. P. 428-429.
12. Bailie G., Clark A., Lane Ch., Lane P. Hypersensitivity reactions and deaths associated with intravenous iron preparation // NDT. 2005. Vol. 20. Р. 1443-1449.
13. Baird I., Podmore D. Intra-muscular iron therapy in iron deficiency anemia // Lancet. 1954. Vol. 2. P. 942.
14. Barton A., Boyd A., McQuade Ch. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis // Pharmacotherapy. 2007. Vol. 27. P. 343-350.
15. Becker C., Macblegor R., Walker K., Jaudl J. Fatal anaphylaxis after intramuscular iron dextran // Ann Intern Med. 1966. Vol. 65. P. 745-748.
16. Bielory L. Serum sickness from iron dextran administration // Acta haematol. 1990. Vol. 83. P. 166-168.
17. Blaud P. Sur les maladies chlorotiques et sur un mode de traitment specifique dons ces affecions // Rev Med Fr Etrang. 1832. Vol. 45. P. 357-367.
18. Brain A., Walters B., Van Wyck D. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients // NDT. 2005. Vol. 20. P. 1438-1442.
19. Breborowicz M., Polubiuska A., Tam P. et al. Effect of iron sucrose on human peritoneal mesothelial cells // Eur J Clin Investig 2003. Vol. 33. P. 1038-1044.
20. Calvar C., Mata D., Alonso C. et al. Intravenous administration of iron gluconate during haemodialysis // NDT. 1997. Vol. 12. P. 574-575.
21. Case G. Maintaining iron balance with total dose infusion of intravenous iron dextran // ANNA J. 1998. Vol. 25. P. 65-68.
22. Charytan Ch., Levin N., Al-Saloum M. et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial // Am J Kidney Dis. 2001. Vol. 37. P. 300-307.
23. Charytan Ch., Schwenk M., Al-Saloum M. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products // Nephron. 2004. Vol. 96. P. 263-266.
24. Chen Y., Ho K., Xia Q. et al. Hydrogen peroxide enhances iron-induced injury in isolated heart and ventricular cardiomyocyte in rats // Mol Cell Biochem. 2002. Vol. 231. P. 61-68.
25. Chertow G., Mason Ph., Vaage-Nielsen O., Ahlenen J. On the relative safety of parenteral iron formulation // NDT. 2004. Vol. 19. P. 1571-1575.
26. Chertow G., Mason Ph., Vaage-Nilson, Ahlenen J. Update on adverse drug events associated with parenteral iron // NDT. 2006. Vol. 21. P. 378-382.
27. Cox J., King R. Valency investigations of iron dextran (Imferon) // Nature. 1965. Vol. 207. P. 1202-1203.
28. Coyne D., Adkinson F., Nissenson A. et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reaction in iron dextran-sensitive and dextran-tolerant patients // Kidney int. 2003. Vol. 63. P. 217-224.
29. Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low molecular weight iron dextran and iron sucrose). A systematic review // Transfusion Altern Transfusion Med. 2007. Vol. 9. P. 8-36.
30. Crockett R., Baillod R., Lee B. et al. Maintenance of fifty patients on intermittent hemodialysis without blood transfusion // Proc EDTA. 1967. P. 17-22.
31. DeVita M., Frumkin D., Mittal S. et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients // Clin Nephrol. 2003. Vol. 60. P. 335-340.
32. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure // NDT. 1999. Vol. 19. Suppl. 2. P. 2-46.
33. Fishbane S., Frei G., Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation // Am J Kidney Dis. 1995. Vol. 26. P. 41-46.
34. Flament J., Goldman M., Waterlot Y. et al. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload // Clin Nephrol. 1986. Vol. 25. P. 227-230.
35. Fleming L., Hopwood D., Shepherd A., Stewart W. Hepatic iron in dialysed patients given intravenous iron dextran // J Clin Pathol. 1990. Vol. 43. P. 119-124.
36. Fletes R., Lazarus M., Gage J. et al. Suspected iron dextran-related adverse drug events in hemodialysis patients // Am J Kidney Dis. 2001. Vol. 37. P. 743-749.
37. Foulkes W., Swery C., Calam J., Hodson H. Rhabdomyolysis after intramuscular iron dextran in malabsorption // Ann Rheum Dis. 1991. Vol. 50. P. 184-186.
38. Freter S., Davidman M., Lipman M., Bercovitch D. Pulmonary edema: atypical anaphylactoid reaction to intravenous iron dextran // Am J Nephrol. 1997. Vol. 17. P. 477-479.
39. Geisser P., Baer M., Schaub E. Structure/histotoxicity relationship of parenteral iron preparations // Arzneim Forsch/Drug Res. 1992. Vol. 42. P. 1439-1452.
40. Goetisch A., Moore C., Minnich V. Observation on the effects of massive doses of iron given intravenously to patients with hypochromic anemia // Blood. 1946. Vol. 1. P. 129-142.
41. Grasso P. Sarcoma after intramuscular iron infection // Br Med J. 1973. Vol. 2. P. 667.
42. Greenberg G. Sarcoma after intramuscular iron injection // Br Med J. 1976. Vol. 3. P. 1506-1509.
43. Grune T., Sommerburg O., Siems W. Oxidativer Streβ bei Anämie // Nieren and Hochdruckkranch. 1999. Vol. 28. S24-S29.
44. Guz G., Sahinarslan A., Dhondt A. et al. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose // Renal Fail. 2004. Vol. 26. P. 663-672.
45. Hatton R., Portales I., Finlay A. et al. Removal of iron dextran by hemodialysis: an in vitro study // Am J Kidney Dis. 1995. Vol. 26. P. 327-330.
46. Hayshi H., Yano M. Iron cytotoxicity in chronic hepatitis C // J Health Sci. 2002. Vol. 48. P. 227-231.
47. Heath C., Strauss M., Gastle W. Quantitative aspects of iron deficiency in hypochromic anemia // J Clin Investig. 1932. Vol. 11. P. 1293-1312.
48. Hoen B., Paul-Danephin A., Hestin D. et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients // J Am Soc Nephrol. 1998. Vol. 9. P. 869-876.
49. Humatra R., Block M., Schocket A. Intravenous iron dextran in clinical medicine // JAMA. 1980. Vol. 243. P. 1726-1731.
50. Kankaraddi V., Hoskatti C., Nadig V. et al. Comparative therapeutic study of TDI and IM injection of iron dextran complex in anemia // J Assoc Physician India. 1973. Vol. 21. P. 849-853.
51. Kapoian T., O'Mara N., Singh A. et al. Ferric gluconate reduces epoietin requirements in hemodialysis patients with elevated ferritin // J Am Soc Nephrol. 2008. Vol. 19. P. 372-379.
52. Kooistra M., Kersting S., Gosriwatana I. et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion // Eur J Clin Investig. 2002. Vol. 32. Suppl. 1. P. 36-41.
53. Locatelli F., Canand B., Eckard K. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome // NDT. 2003. Vol. 18. P. 1272-1280.
54. Malindres P., Sioulis A., Avgerion E. et al. Associated between intensive intravenous iron treatment and angina pectoris in hemodialysis patients // Clin Nephrol. 2006. Vol. 66. P. 312-313.
55. Manuel M., Stewart W., Clair N., Hutchinson F. Loss of iron-dextran through cuprophane membrane of disposable coil dialyser // Nephron. 1972. Vol. 9. P. 94-98.
56. McCardy P. Oral and parenteral iron therapy: a comparison // JAMA. 1965. Vol. 191. P. 155-158.
57. McCarthy J., Regnier C., Loebertmann C., Bergstralh E. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran - a comparison of two products // Am J Nephrol. 2000. Vol. 20. P. 455-462.
58. Miceli M., Dong L., Grazziutti M. et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients // Bone Marrow Transplant. 2006. Vol. 37. P. 857-864.
59. Mircescu G., Garmata L., Capusa C., Ursea N. Intravenous iron supplementation for the treatment of anemia in pre-dialyzed chronic renal failure patients // NDT. 2006. Vol. 21. P. 120-124.
60. Mircescu G., Garneata L., Capusa C., Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients // NDT. 2006. Vol. 21. P. 120-124.
61. Moniem K., Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients: a comparison of preparations // Transfusion Altern Transfusion Med. 2007. Vol. 9. P. 37-42.
62. Moniem K., Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients // J Am Soc Nephrol. 2003. Vol. 14. 705A.
63. Mossey R., Sondheimer J. Listeriosis in patients with long term hemodialysis and transfusional iron overload // Am J Med. 1985. Vol. 79. P. 397-400.
64. Mudge H., Weiner I. Agents affecting volume and composition of body fluids / In: The Pharmacological Basis of Therapeutics. New York, Pergamon Press, 1990. P. 682-707.
65. Müller A. Arzneim-Forsch Drug Res, 1974. Vol. 24. P. 880.
66. Nanas J. Etiology of anemia in patients with advanced heart failure // J Am Coll Cardiol. 2006. Vol. 48. P. 2485-2489.
67. Nissim J. Intravenous administration of iron // Lancet. 1947. Vol. 1. P. 49-51.
68. Oh V. Iron dextran and systemic lupus erythematosus // Brit J Med. 1992. Vol. 305. P. 1000.
69. Okonko D., Grzeslo A., Witkowski T. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and non-anemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF a randomized controlled observer-blinded trial // J Am Coll Cardiol. 2008. P. 103-112.
70. Patruta S., Edlinger R., Sunder-Plassman G., Hörl W. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency // J Am Soc Nephrol. 1998. Vol. 9. P. 655-663.
71. Peck S., Piccoli D., Baldassano R. Safety and efficacy of iron dextran infusions in children with inflammatory bowel disease and iron deficiency anemia // J Pediatr Gastroenterol and Nutrition. 1998. Vol. 27. P. 487.
72. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure // NDT. 2004. Vol. 19. Suppl. 2. P. 2-46.
73. Rooyakkers T., Stroes E., Kooistra M. et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo // Eur J Clin Investig. 2002. Vol. 32. Suppl. 1. P. 9-16.
74. Saltissi D., Sauvage D., Westhuyzen J. Comparative response to single or divided doses of parenteral iron for functional deficiency in hemodialysis patients receiving erythropoietin (EPO) // Clin Nephrol. 1998. Vol. 49. P. 45-48.
75. Sanai T., Oochi N., Okada M. et al. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats // J Lab Clin Med. 2005. Vol. 146. P. 25-29.
76. Sane R., Baribeault D., Rosenberg C. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate // Pharmacotherapy. 2007. Vol. 27. P. 613-615.
77. Sargent J., Acchiardo S. Iron requirements in hemodialysis // Blood Purif. 2004. Vol. 22. P. 112-123.
78. Sav T., Tokgoz B., Sipahioglu M. et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? // Renal failure. 2007. Vol. 29. P. 423-426.
79. Schaefer R. Safety of intravenous iron dextran in patients receiving haemodialysis. Erythropoiesis: new dimensions in the treatment anaemia //NDT. 1997. Vol. 8. P. 49-50.
80. Schiller B., Doss S., De Cock E. et al. Activity based cost analysis of in center anemia treatment in hemodialysis patients. // NKF 2007 Spring Clinical Meeting. Orlando, 2007. abstr. 248.
81. Schwenk M., Blaustein D. Rapid, high-dose intravenous iron sucrose therapy in 2 Jehovah’s Witness patient with severe anemia, iron deficiency and chronic kidney disease // Clin Nephrol. 2004. Vol. 62. P. 116-120.
82. Senger J., Weiss R. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment // ANNA J. 1996. Vol. 23. P. 319-323.
83. Sepandj F., Jindal K., West M., Hirschu D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients // NDT. 1996. Vol. 11. P. 319-322.
84. Sharma J. A prospective, partially randomized study of pregnancy outcomes and hematologic responses to oral and intramuscular iron treatment in moderately anemic pregnant women // Am J Clin Nutr. 2004. Vol. 79. P. 116-122.
85. Siems W., Carinccio F., Grune T. et al. Elevated concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia // Clin Nephrol. 2002. Vol. 58. Suppl. 1. P. 20-25.
86. Silverberg D., Blum M., Aglaria Z. et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period // Clin Nephrol. 2001. Vol. 55. P. 212-219.
87. Singh A., Patel T., Hertel J. et al. Safety of ferumoxytol in patients with anemia and CKD // Am J Kidney Dis. 2008. Vol. 52. P. 907-915.
88. Stockman R. The treatments of chlorosis with iron and some other drugs // Brit Med J. 1893. Vol. 1. P. 881-885.
89. Strickland I., Chaput de Saintouge et al. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients // Clin Nephrol. 1977. Vol. 7. P. 55-57.
90. Van Wick D., Cavallo G., Spinowitz B. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North Amerrican clinical trial // Am J Kidney Dis. 2000. Vol. 36. P. 88-97.
91. Van Wick D., Roppolo M., Martinez C. et al. A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis-dependent CKD // Kidney int. 2005. Vol. 68. P. 2846-2856.
92. Van Wyek D., Cavallo G., Spinowitz B. et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran. North American Clinical Trial // Am J Kidney Dis. 2000. Vol. 36. P. 88-97.
93. Wallenstein R. Intravenous iron-dextran complex // Blood. 1998. Vol. 32. P. 690-695.
94. Waterlot Y., Cantinieaux B., Harcia-Muller Ch. et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload // Brit Med J. 1985. Vol. 291. P. 501-504.
95. Wood J. The Metabolism of iron-dextran given as a total-dose infusion to iron deficient jamaican subjects // Brit J Haematol. 1968. Vol. 14. P. 119-129.
96. Yee J., Besarab A. Iron sucrose: the oldest iron therapy becomes news // Am J Kidney Dis. 2002. Vol. 40. P. 1111-1121.
97. Zager R., Johnson A., Hanson Sh. et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cells injury // Am J Kidney Dis. 2002. Vol. 40. P. 90-103.
98. Zager R., Johnson A., Hanson Sh. Parenteral iron exacerbates experimental sepsis // Kidney int. 2004. Vol. 65. P. 2108-2112.
99. Zager R., Johnson A., Hanson Sh. Parenteral iron nephrotoxicity: potential mechanisms // Kidney int. 2004. Vol. 66. P. 144-156.
100. Zager R., Johnson A., Hanson Sh., Zund S. Parenteral compounds sensitize mice to injury-initiated TNF alfa release // Am J Physiol. 2005. Vol. 288. F295-F297.
101. Zeligson A. Anaphylactic shock after intravenous Imferon // Harefuah. 1970. Vol. 79. P. 283.
102. Zhao Z., Cheng G., Xiao J. et al. Intravenous infusion of total dose iron dextran in treatment anemia for peritoneal dialysis patients // Chin J New Drugs Clin Rem. 2005. Vol. 9. P. 750-752.
103. Zheng H., Cable R., Spencer B. et al. Iron stores and vascular function in voluntary blood donors // Arterioscler Tromb Vasc Biol. 2005. Vol. 25. P. 1577-1583.
104. Zipt R. Fatal anaphylaxis after intravenous iron dextran // J Forensic Sci Int. 1976. Vol. 20. P. 326.
Review
For citations:
Ermolenko V.M., Mikhaylova N.A., Baterdene S. Low molecular weight dextran of iron: is it safely for treatment of anemia in patients with chronic kidney disease? Nephrology and Dialysis. 2009;11(2):109-116. (In Russ.)
Views:
6
Email this article 